Upcoming Stock Splits This Week (July 21 to July 25)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
On the flip side, some companies opt for a reverse stock split. Instead of dividing shares, they consolidate them, reducing the share count and boosting the price per share. While the market cap stays the same, this move is typically aimed at meeting minimum price requirements to maintain exchange listings, like Nasdaq's threshold, and avoid delisting.
Whether the goal is to attract retail interest or preserve listing status, these corporate maneuvers can send important signals – and smart traders are always watching.
Let's take a look at the upcoming stock splits for the week.
Invo Fertility (IVF) – Invo Fertility, known for its innovative fertility treatments and its unique INVOcell device, is taking steps to stay in line with Nasdaq's listing requirements. On July 17, the company announced a 1-for-3 reverse stock split to help boost its share price and maintain compliance with the exchange's minimum bid rule. The split will take effect on July 21.
Globavend Holdings (GVH) – Australia-based Globavend Holdings offers cross-border logistics services to e-commerce retailers, focusing on last-mile delivery and freight forwarding. On July 17, the company announced a 1-for-200 reverse stock split of its ordinary shares to increase its share price and meet Nasdaq's continued listing standards. GVH stock is expected to begin trading on a split-adjusted basis on July 21.
Top Wealth Group Holding (TWG) – Hong Kong-based Top Wealth Group is engaged in environmental consulting, caviar production, and waste treatment services. On July 17, the company announced a 1-for-90 reverse stock split of its ordinary shares to regain compliance with Nasdaq's $1 minimum bid price rule and support its pending merger with Jilin Xiuzheng Agriculture & Animal Husbandry. TWG stock is expected to begin trading on a split-adjusted basis on July 21.
CNS Pharmaceuticals (CNSP) – CNS Pharmaceuticals is a biotechnology company focused on developing anticancer drugs for primary and metastatic cancers of the brain and central nervous system. On July 15, the company announced a 1-for-12 reverse stock split of its common shares to comply with Nasdaq's minimum bid requirement. CNSP stock is expected to begin trading on a split-adjusted basis on July 22.
Generation Bio (GBIO) – Focused on tackling rare and common genetic diseases, Generation Bio is developing next-gen non-viral gene therapies using its own closed-ended DNA platform. On July 18, the company announced a 1-for-10 reverse stock split to boost its share price and stay in compliance with Nasdaq listing rules. GBIO shares will begin trading on a split-adjusted basis starting July 22.
Premium Catering Holdings (PC) – Serving up large-scale halal meals across Asia, Premium Catering Holdings is a key player in feeding construction crews and corporate events alike. On July 17, the Hong Kong-based company announced a 1-for-9 reverse stock split of its ordinary shares, a move aimed at boosting its share price and staying in line with Nasdaq's listing standards. PC stock is set to start trading on a split-adjusted basis on July 22.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
LGI (ASX:LGI) Shareholders Will Want The ROCE Trajectory To Continue
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. So on that note, LGI (ASX:LGI) looks quite promising in regards to its trends of return on capital. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. What Is Return On Capital Employed (ROCE)? For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for LGI: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.11 = AU$9.6m ÷ (AU$95m - AU$9.9m) (Based on the trailing twelve months to December 2024). Thus, LGI has an ROCE of 11%. By itself that's a normal return on capital and it's in line with the industry's average returns of 11%. Check out our latest analysis for LGI Above you can see how the current ROCE for LGI compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for LGI . The Trend Of ROCE Investors would be pleased with what's happening at LGI. The data shows that returns on capital have increased substantially over the last five years to 11%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 184%. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed. The Bottom Line A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what LGI has. And with a respectable 11% awarded to those who held the stock over the last year, you could argue that these developments are starting to get the attention they deserve. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence. On a separate note, we've found 1 warning sign for LGI you'll probably want to know about. While LGI may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Investors in Genetic Signatures (ASX:GSS) have unfortunately lost 85% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held Genetic Signatures Limited (ASX:GSS) for five whole years - as the share price tanked 85%. And we doubt long term believers are the only worried holders, since the stock price has declined 49% over the last twelve months. On the other hand the share price has bounced 8.2% over the last week. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Genetic Signatures wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over half a decade Genetic Signatures reduced its trailing twelve month revenue by 2.3% for each year. While far from catastrophic that is not good. The share price fall of 13% (per year, over five years) is a stern reminder that money-losing companies are expected to grow revenue. It takes a certain kind of mental fortitude (or recklessness) to buy shares in a company that loses money and doesn't grow revenue. Fear of becoming a 'bagholder' may be keeping people away from this stock. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). If you are thinking of buying or selling Genetic Signatures stock, you should check out this FREE detailed report on its balance sheet. A Different Perspective While the broader market gained around 13% in the last year, Genetic Signatures shareholders lost 49%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 13% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 3 warning signs we've spotted with Genetic Signatures . But note: Genetic Signatures may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Insider
32 minutes ago
- Business Insider
Thomson Reuters to join Nasdaq-100 Index on July 28
Nasdaq announced that Thomson Reuters (TRI), will become a component of the Nasdaq-100 Index and the Nasdaq-100 Equal Weighted Index prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS (ANSS) in the Nasdaq-100 Index and the Nasdaq-100 Equal Weighted Index. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
